New Yale Research Reveals Why Immunotherapy Doesn T Work For Everybody
A recent study conducted by Yale School of Medicine researchers recently published in the journal Cancer Discovery has uncovered a possible explanation for why this occurs. According to an analysis of a phase 2 study involving 24 patients with endometrial cancer and the immunotherapy drug pembrolizumab, the Yale team pinpoints a specific mechanism of faulty DNA repair in tumors as a key factor in determining patient outcomes. “We wanted to understand why some patients respond better than others to immunotherapy,” said co-corresponding author Ryan Chow, an M....